

This spreadsheet is updated monthly and enables self-audit of a medicines formulary for adherence to current NICE Technology Appraisals. All guidelines refer to adults unless indicated.

Technology appraisals 33  
 ICB commissioned 5  
 Non-ICB commissioned 16  
 Not applicable 12  
 ICB commissioned and approved 1 (20%)  
 Average days to compliance 27

Title	Recommendation	Published	Type	Implement	Commissioner	ICB decision	Compliance	Notes	Local information
<a href="#">Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic gastric or gastro-oesophageal junction cancer after anti-HER2 treatment (terminated appraisal) [TA879]</a>	Terminated appraisal	06/04/2023	TA					N/A	Terminated appraisal
<a href="#">Tezepelumab for treating severe asthma [TA880]</a>	Recommended	20/04/2023	TA	19/07/2023	Non-ICB			This technology is commissioned by NHS England. Providers are NHS hospital trusts.	NHS England
<a href="#">Ripretinib for treating advanced gastrointestinal stromal tumour after 3 or more treatments [TA881]</a>	Not recommended	03/05/2023	TA					N/A	Not recommended
<a href="#">Voclosporin with mycophenolate mofetil for treating lupus nephritis[TA882]</a>	Recommended	03/05/2023	TA	01/08/2023	Non-ICB			This technology is commissioned by NHS England. Providers are NHS hospital trusts.	NHS England
<a href="#">Tafasitamab with lenalidomide for treating relapsed or refractory diffuse large B-cell lymphoma[TA883]</a>	Not recommended	03/05/2023	TA					N/A	Not recommended
<a href="#">Capmatinib for treating advanced non-small-cell lung cancer with MET exon 14 skipping (terminated appraisal)[TA884]</a>	Terminated appraisal	03/05/2023	TA					N/A	Terminated appraisal
<a href="#">Pembrolizumab plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancer[TA885]</a>	Recommended	03/05/2023	TA	01/08/2023	Non-ICB			This technology is commissioned by NHS England. Providers are NHS hospital trusts.	NHS England
<a href="#">Olaparib for adjuvant treatment of BRCA mutation-positive HER2-negative high-risk early breast cancer after chemotherapy[TA886]</a>	Recommended	10/05/2023	TA	08/08/2023	Non-ICB			This technology is commissioned by NHS England. Providers are NHS hospital trusts.	NHS England
<a href="#">Olaparib for previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer[TA887]</a>	Recommended	10/05/2023	TA	08/08/2023	Non-ICB			This technology is commissioned by NHS England. Providers are NHS hospital trusts.	NHS England
<a href="#">Risankizumab for previously treated moderately to severely active Crohn's disease[TA888]</a>	Recommended	17/05/2023	TA (EAMS)	TBC	ICB			Commissioned by ICBs for adults and by NHS England for people aged 16 to 17 years. 30-day implementation period applies after TA publication or the date that the on-body device receives CE marking, whichever is later.	Grey statement, pending availability of on-body device

Title	Recommendation	Published	Type	Implement	Commissioner	ICB decision	Compliance	Notes	Local information
<a href="#">Ciltacabtagene autoleucl for treating relapsed or refractory multiple myeloma (terminated appraisal) [TA889]</a>	Terminated appraisal	17/05/2023	TA					N/A	Terminated appraisal
<a href="#">Difelikefalin for treating pruritus in people having haemodialysis [TA890]</a>	Recommended	17/05/2023	TA	15/08/2023	Non-ICB			This technology is commissioned by NHS England. Providers are NHS hospital trusts.	NHS England
<a href="#">Ibrutinib with venetoclax for untreated chronic lymphocytic leukaemia [TA891]</a>	Recommended	31/05/2023	TA	29/08/2023	Non-ICB			This technology is commissioned by NHS England. Providers are NHS hospital trusts.	NHS England
<a href="#">Mosunetuzumab for treating relapsed or refractory follicular lymphoma [TA892]</a>	Not recommended	31/05/2023	TA					N/A	Not recommended
<a href="#">Brexucabtagene autoleucl for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people 26 years and over [TA893]</a>	Recommended	07/06/2023	TA	05/09/2023	Non-ICB			This technology is commissioned by NHS England. Providers are NHS hospital trusts. CDF.	NHS England
<a href="#">Axicabtagene ciloleucl for treating relapsed or refractory follicular lymphoma [TA894]</a>	Not recommended	07/06/2023	TA					N/A	Not recommended
<a href="#">Axicabtagene ciloleucl for treating relapsed or refractory diffuse large B-cell lymphoma after first-line chemoimmunotherapy [TA895]</a>	Recommended	07/06/2023	TA	05/09/2023	Non-ICB			This technology is commissioned by NHS England. Providers are NHS hospital trusts. CDF.	NHS England
<a href="#">Bulevirtide for treating chronic hepatitis D [TA896]</a>	Recommended	07/06/2023	TA	05/09/2023	Non-ICB			This technology is commissioned by NHS England. Providers are NHS hospital trusts	NHS England
<a href="#">Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma [TA897]</a>	Recommended	06/06/2023	TA	04/09/2023	Non-ICB			This technology is commissioned by NHS England. Providers are NHS hospital trusts	NHS England
<a href="#">Dabrafenib plus trametinib for treating BRAF V600 mutation-positive advanced non-small-cell lung cancer [TA898]</a>	Recommended	14/06/2023	TA	12/09/2023	Non-ICB			This technology is commissioned by NHS England. Providers are NHS hospital trusts	NHS England
<a href="#">Esketamine for treating major depressive disorder in adults at imminent risk of suicide (terminated appraisal) [TA899]</a>	Terminated appraisal	06/06/2023	TA					N/A	Terminated appraisal
<a href="#">Tixagevimab plus cilgavimab for preventing COVID-19 [TA900]</a>	Not recommended	14/06/2023	TA					N/A	Not recommended
<a href="#">Cemiplimab for treating recurrent or metastatic cervical cancer (terminated appraisal) [TA901]</a>	Terminated appraisal	20/06/2023	TA					N/A	Terminated appraisal

Title	Recommendation	Published	Type	Implement	Commissioner	ICB decision	Compliance	Notes	Local information
<a href="#">Dapagliflozin for treating chronic heart failure with preserved or mildly reduced ejection fraction [TA902]</a>	Recommended	21/06/2023	TA	19/09/2023	ICB			This technology is commissioned by integrated care boards. Providers are NHS hospital trusts.	Amber recommended statement
<a href="#">Darolutamide with androgen deprivation therapy and docetaxel for treating hormone-sensitive metastatic prostate cancer [TA903]</a>	Recommended	21/06/2023	TA	19/09/2023	Non-ICB			This technology is commissioned by NHS England. Providers are NHS hospital trusts	NHS England
<a href="#">Pembrolizumab with lenvatinib for previously treated advanced or recurrent endometrial cancer [TA904]</a>	Recommended	21/06/2023	TA	19/09/2023	Non-ICB			This technology is commissioned by NHS England. Providers are NHS hospital trusts	NHS England
<a href="#">Upadacitinib for previously treated moderately to severely active Crohn's disease [TA905]</a>	Recommended	21/06/2023	TA (Cost comparison)	21/07/2023	ICB	18/07/2023	27	This technology is commissioned by integrated care boards. Providers are NHS hospital trusts.	Red statement
<a href="#">Deucravacitinib for treating moderate to severe plaque psoriasis [TA907]</a>	Recommended	28/06/2023	TA	26/09/2023	ICB			This technology is commissioned by integrated care boards. Providers are NHS hospital trusts.	Red statement
<a href="#">Rimegepant for preventing migraine [TA906]</a>	Recommended	05/07/2023	TA	03/10/2023	ICB			Rimegepant is commissioned by integrated care boards. Providers are NHS hospital trusts or primary care practitioners, possibly with specialist involvement through shared care agreements or advice and guidance (please see primary care approach section in the guidance).	Amber retained statement
<a href="#">Olaparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube or peritoneal cancer after 2 or more courses of platinum-based chemotherapy [TA908]</a>	Recommended	05/07/2023	TA	03/10/2023	Non-ICB			This technology is commissioned by NHS England. Providers are NHS hospital trusts.	
<a href="#">Lorlatinib for untreated ALK-positive advanced non-small-cell lung cancer [TA909]</a>	Not recommended	12/07/2023	TA					N/A	Not recommended
<a href="#">Semaglutide for managing overweight and obesity in young people aged 12 to 17 years (terminated appraisal) [TA910]</a>	Terminated appraisal	13/07/2023	TA					N/A	Terminated appraisal
<a href="#">Selpercatinib for untreated RET fusion-positive advanced non-small-cell lung cancer [TA911]</a>	Recommended	26/07/2023	TA	24/10/2023	Non-ICB			This technology is commissioned by NHS England. Providers are NHS hospital trusts. The resource impact of selpercatinib will be covered by the Cancer Drugs Fund budget.	NHS England